Background: Academic medical centers (AMCs) have increasingly adopted conflict of interest policies governing physician-industry relationships; it is unclear how policies impact prescribing.
P hysicians' interactions with the pharmaceutical industry begin early in training, 1 and take many forms including receipt of gifts, promotional contact with sales representatives, and participation in industry-sponsored continuing medical education and research. 2 These interactions have been shown to influence physicians' choice of medication, which in some cases is associated with higher costs. 3 Increasingly, the financial relationships between physicians and industry and the potential conflicts of interest (COI) arising from these relationships has garnered substantial policy attention. 4 Regulating professional-industry interactions to mitigate COI may be most challenging in academic medical centers (AMCs), where physicians conduct research, teach students, and supervise residents and fellows in addition to providing patient care.
Initial recommendations on regulation of physicianindustry interactions in academic settings was focused on human subjects research activities. Between 2007 and 2009, the Institute of Medicine, 4 American Association of Medical Colleges (AAMC), 5, 6 and the American Medical Association (AMA) 7 issued new policy recommendations focused on physician-industry interactions pertaining to clinical practice and medical education within AMCs. Institutions responded with a host of policies including public disclosure of remuneration from industry, which can approach income from patient care for some physicians, 8, 9 bans on gifts and other forms of promotion known to influence prescribing, 10, 11 and restrictions on funding of continuing medical education. 12 It is important but challenging to determine the influence such COI policies have on physician prescribing. The Institute of Medicine states the objectives of policies include preserving public trust and professional integrity but also pointed to more measurable effects such as increasing "evidence-based physician prescribing practices." 4 This point is particularly salient for drug classes such as antipsychotics, for which numerous choices exist without a clear first-line treatment but with variation in prices and side-effect profiles. Research on the impact of COI policies has focused on trainees only with mixed results, [13] [14] [15] whereas no studies have been examined the impact of policies on practicing physicians. Nor do we know how the prescribing practices of academic physicians compare with those in the community where restrictions on physician-industry relationships are far less common.
We examined prescribing of heavily promoted antipsychotics among psychiatrists affiliated with AMCs with varying adoption of COI policies as well as psychiatrists in nonacademic settings between 2008 and 2011. Secondly, we examined prescribing of new and reformulated antipsychotics, which have been introduced and adopted during the era of COI regulation. We chose antipsychotics for several reasons. Antipsychotics have consistently ranked among the 5 highest selling drug classes in recent years. 16 Physicians have many brand and generic options within the antipsychotic category with large randomized trials reporting comparable effectiveness among newer and older antipsychotics. [17] [18] [19] Yet, new antipsychotics were rapidly adopted by physicians 20 due to the lower risk of some side effects and also due to widespread off-label marketing and use. [21] [22] [23] Thus, we expect antipsychotic prescribing patterns to be sensitive to changes in policies restricting physicianindustry interactions.
METHODS

Data Sources
We obtained 3 types of physician-level data from IMS Health. First, we obtained physician-level data on prescriptions dispensed for antipsychotics from the Xponent database, which directly captures over 70% of all US prescriptions filled in retail pharmacies and uses a patented proprietary projection methodology to represent 100% of prescriptions filled in these outlets. We obtained data on all monthly antipsychotic prescriptions from 2008 to 2011 for all US psychiatrists with >10 antipsychotic prescriptions in 2011. Xponent includes physician-level data on the number of filled prescriptions for all first-generation and second-generation antipsychotic products regardless of payer for patients of all ages. Second, IMS Health provided AMA Masterfile data linked to Xponent prescribing data. AMA Masterfile data, which is not limited to AMA members, includes prescriber characteristics such as demographics and medical education. Third, longitudinal information on each physician's organizational affiliations, including academic affiliations and organization size and specialty, was obtained from IMS Health's Healthcare Organizational Services Database, which captures physicians' affiliations with over 29,000 practices, clinics, hospitals, and integrated health systems. 24 This information was used to classify psychiatrists as academic or nonacademic affiliated and to classify academic psychiatrists based on exposure to different COI policies.
To identify heavily promoted antipsychotics, we obtained monthly product-level promotion data from IMS Health's Integrated Promotional Services Audit, which tracks spending by pharmaceutical manufacturers on free samples, sales representatives' contacts with physicians, and other promotion.
Sample Definition and Affiliation Variables
We classified the psychiatrist population by academic affiliation. First, we identified psychiatrists affiliated with a hospital or clinic integrated with a single AMC throughout the study period, assuming that institutional policies have a stronger effect in integrated centers than in hospitals with separate administrative operations. Using the AAMC Organization Characteristics Database 25 we identified integrated AMC hospitals (under common ownership with a medical school, or with a majority of medical school department chairs serving as hospital chiefs of service). Clinics were connected to teaching hospitals if they shared the organization name and city. Of the 135 US allopathic medical schools, 102 had integrated hospitals and 101 had identifiable COI policies and were thus included in the study (Supplemental Fig. 1 , Supplemental Digital Content 1, http:// links.lww.com/MLR/A872).
To examine secular trends in antipsychotic prescribing, we also collected data on psychiatrists with no academic affiliation from 2008 to 2011. These nonacademic psychiatrists could be in private outpatient practice or affiliated with a non-AMC hospital. We excluded psychiatrists affiliated with Kaiser Permanente or Veterans Affairs health centers because prescriptions filled in Kaiser or Veterans Affairs pharmacies are not captured by Xponent.
COI Policies
Longitudinal information on policies for the 101 integrated AMCs was obtained from the American Medical Student Association's PharmFree Scorecard 26 and Columbia University's Institute on Medicine as a Profession database. 27 Both databases collect information on policies from public Web sites and from institutions directly and have been used in previous studies. [12] [13] [14] [15] We reviewed policy descriptions for 9 domains ( 
Key Independent Variables
Consensus is lacking on which COI policies are the most important and on the appropriate stringency. Previous studies examined the impact of bans on gifts alone. 14 However, most AMCs have adopted several additional policies often simultaneously, making it difficult to disentangle the effects of each policy. Our independent variable was affiliation with an AMC with a stringent set of policies. Our benchmark was compliance with the AAMC standard for each policy domain (Supplemental Table 1 , Supplemental Digital Content 2, http://links.lww.com/MLR/A873). 6 As only 2 of 101 schools were compliant with all 9 AAMC recommendations by 2011, we chose a cutoff of Z7/9 compliant policies for stringency among academically affiliated psychiatrists. We categorized academically affiliated psychiatrists into 3 groups based on whether their institution: (1) was "AAMC compliant throughout" (Z7/9 policies compliant with AAMC recommendations throughout the study period), (2) "attained AAMC compliance" (Z7/9 policies compliant after 2008), or (3) was "never AAMC compliant" (< 7/9 policies AAMC compliant throughout). No institution loosened its policies during the period. The fourth group of physicians was not affiliated with an academic institution at any point during the study period. We assume this group was exposed to few, if any, external restrictions on interactions with industry during the study period. Identification for the effect of a set of AAMC-compliant COI policies comes from comparing differences in prescribing between 2008 and 2011 among psychiatrists affiliated with academic institutions that had AAMC-compliant COI policies in 2011 but not in 2008 (the attained AAMC-compliant group) with 2008-2011 prescribing differences among psychiatrists in the other 3 groups (AAMC compliant throughout, never AAMC compliant, and nonacademic). Thus, the key independent variables in this difference-in-differences model specification are year (2011 vs. 2008), physician group (3 academic groups and 1 nonacademic group), and interaction terms between each physician group and year.
Dependent Variables
We constructed 2 measures of prescribing behaviors. First, we measured the number of a psychiatrist's antipsychotic prescriptions filled for heavily promoted products defined as products averaging >50,000 detailing contacts annually from 2008 through 2011 (Supplemental Table 2 , Supplemental Digital Content 3, http://links.lww.com/MLR/ A874). Second, we examined the combined number of a psychiatrist's antipsychotic prescriptions for new (introduced after 2006) and orally administered reformulated products. New products included: asenapine, paliperidone, iloperidone, and lurasidone. Reformulations included dissolvable tablet reformulations of olanzapine, aripiprazole, and risperdione (Zyprexa Zydis, Abilify Discmelt, Risperdal ODT, respectively); extended-release formulations of quetiapine (Seroquel XR); and a fixed-dose combination of olanzapine and fluoxetine (Symbyax).
Covariates
Prescribing behavior varies by physician demographic characteristics, specialty, medical education, and practice setting. 20, [28] [29] [30] Therefore, our analyses adjusted for the following covariates: decade of medical school graduation, sex, psychiatric subspecialty training, training at a top 20 medical school based on 2011 US News and World Report Rankings, training at a foreign medical school, and practice setting (inpatient only, both inpatient and outpatient practice, or outpatient only; affiliation with a behavioral health specialty hospital or clinic). We also adjusted for available measures of a physician's patient caseload (% of antipsychotic prescriptions paid for by Medicare or Medicaid as a proxy for disability, and % of prescriptions filled by adults). To adjust for regional variation in use of newer drugs, we included indicator variables for Census Division.
Statistical Analysis
We created graphical summaries of the number of a psychiatrist's heavily promoted antipsychotic prescriptions filled and of the number of a psychiatrist's new or reformulated antipsychotic prescriptions filled on a quarterly basis for 2008 through 2011. We estimated nonlinear mixed regression models assuming the number of heavily promoted antipsychotics (or new/reformulated antipsychotics) per physician arose from binomial distributions. 31 We used a logit link to estimate the associations of the physician group, time (an indicator variable = 1 for prescriptions written in 2011, and 0 otherwise), and their interactions, adjusting for all covariates described above. We included a random physician term to adjust for clustering and variable prescription volumes. Twotailed tests with P < 0.05 were considered significant. Our main interest is the coefficient on the interaction term between physician group and 2011. We exponentiated the coefficient of the interaction term to obtain odds ratios (2011 vs. 2008) for both groups of academic psychiatrists whose institutions adopted COI policies and the nonacademic group relative to the reference group (the never-AAMC-compliant group) as relative odds ratios (ROR). In addition, we transformed the regression coefficients from the log-odds scale to the probability scale and used bootstrapping techniques to summarize results. We randomly sampled physicians with replacement and estimated the mean difference-in-difference in the probability of prescribing heavily promoted (or new/reformulated) antipsychotics. We repeated this process 500 times to determine confidence intervals (CIs) across the bootstrapped samples. Ninety-five percent CIs were determined by ranking the difference-in-difference across the 500 samples and identifying the 2.5 and 97.5 percentiles. All analyses were conducted in SAS version 9.3 (SAS Institute Inc., Cary, NC). The University of Pittsburgh Institutional Review Board approved this study.
We conducted 3 sensitivity analyses. First, we applied a less stringent cutoff for AAMC compliance (Z5/9 instead of Z7/9). Second, we estimated a physician fixed effects model to control for all time-invariant physician characteristics, including unmeasured variables. Third, to adjust for clustering by AMC, we ran mixed models on the subset of academically affiliated physicians only that adjusted for clustering both at the physician level and the institution level. Our results were robust to these alternate specifications, so we present only the primary analyses.
RESULTS
Characteristics of the Study Sample
There were 5239 psychiatrists who were affiliated with integrated AMCs at any point during 2008-2011. Of those, 2464 were affiliated with the same AMC throughout and were thus included in our analysis. We identified 11,201 psychiatrists consistently practicing in nonacademic settings in the same period. Academic psychiatrists were more likely to practice in inpatient settings, and to be recent medical school graduates, and less likely to have graduated from a foreign medical school than were nonacademic psychiatrists ( Table 1) .
Adoption of COI Policies by AMCs
Of the 101 AMCs with integrated hospitals, only 10 were AAMC compliant in 2008. The mean number of AAMC-recommended policies adopted by these compliant AMCs was similar in 2008 (7.3) and 2011 (7.5) . Another 30 attained compliance during the study period, increasing the mean number of AAMC policies from 3.2 to 7.5. The 61 AMCs deemed "never AAMC compliant" only increased the mean number of policies from 2.9 to 4.7 between 2008 and 2011.
Exposure to COI Policies Among Psychiatrists
In our sample, 376 (15%) psychiatrists were affiliated with academic centers that were AAMC compliant throughout, 576 (23%) with centers attaining AAMC compliance, and 1512 (61%) with never-AAMC-compliant centers ( Table 1) . Uptake of AAMC policy recommendations by AMCs varied by domain. For example, in 2011, over 90% of psychiatrists were exposed to AAMC-compliant policies on sales representative site access versus <20% to policies requiring public disclosure of financial relationships with industry ( Fig. 1 ).
Market Share for Heavily Promoted Antipsychotics
The 13,665 physicians in our sample wrote 47.7 million antipsychotics prescriptions that were filled between January 2008 and December 2011. The share of prescriptions written for heavily promoted antipsychotics was remarkably consistent over time and across groups. In 2008, 63.0% of antipsychotic prescriptions by psychiatrists in AAMC-compliant centers were for heavily promoted products versus 65.3% for psychiatrists in centers attaining AAMC compliance and 63.9% of psychiatrists in never-AAMC-compliant centers (Fig. 2) . In 2011, the corresponding shares were 63.7%, 62.7%, and 62.7% for these groups, respectively. Nonacademic psychiatrists had a similar level and stable trend in prescribing for heavily promoted products (65.6% in 2008 vs. 64.4% in 2011).
After adjusting for a number of physician characteristics, psychiatrists in centers that attained AAMC compliance had a slightly larger decrease in likelihood of prescribing heavily promoted antipsychotics between 2008 and 2011 compared with psychiatrists in never-AAMC-compliant centers (ROR, 0.95; P < 0.0001). This represents a 0.2% relative decrease in the probability of prescribing heavily promoted drugs between groups. There was no significant difference-inthe-differences between the AAMC compliant throughout or nonacademic groups compared with the never-AAMC-compliant group ( Table 2) . Full regression output is provided in Supplemental 
Prescribing of New and Reformulated Antipsychotics
The share of antipsychotic prescriptions for new and reformulated products increased in each physician group. Among the 3 groups of academic psychiatrists the share of prescriptions for new or reformulated products in 2008 was 2.6% in AAMC-compliant centers, 4.1% in centers attaining AAMC compliance, and 5.6% in never-compliant AMCs (Fig. 3) . By 2011, these shares increased to 7.9%, 10.7%, and 10.2%, respectively. Nonacademic psychiatrists increased prescribing of new and reformulated products from 4.8% in 2008 to 11.9% in 2011.
After adjusting for physician characteristics, psychiatrists in AAMC-compliant centers actually had a larger relative increase in prescribing of new/reformulated antipsychotics compared with those in never-AAMC-compliant centers with a ROR of 1.39 (95% CI, 1.35-1.44; P < 0.0001), a 1.1% relative increase. Nonacademic psychiatrists also increased their prescribing of new/reformulated antipsychotics relative to the never-AAMC-compliant academic group with a ROR of 1.16 (95% CI, 1.14-1.18; P < 0.0001), or a 2% relative increase ( Table 2) .
DISCUSSION
In the first study of the impact of COI policies and marketing restrictions on academic attending physicians we report 3 key findings. First, while there was a significant increase in adoption of strict COI policies in recent years, as of 2011, the majority of psychiatrists were affiliated with institutions only partially compliant with AAMC recommendations. Second, affiliation with an AMC adopting strict policies was associated with a small relative decrease in prescribing of heavily promoted antipsychotics and also with a small increase in prescribing of new or reformulated antipsychotics. Third, nonacademic psychiatrists are significantly more likely to prescribe new and reformulated antipsychotics compared with academic psychiatrists, but no more likely to prescribe heavily promoted antipsychotics.
This study adds to the small body of empirical evidence on the impact of COI policies on prescribing. Two prior studies examining prescribing of psychotropic pharmaceuticals found that exposure to restrictive policies during training was associated with small but significant reductions in prescribing of new and heavily promoted pharmaceuticals 2-7 years later. 14, 15 In comparison, our study on attending physicians showed minimal differences in prescribing of new and heavily promoted antipsychotics based upon exposure to restrictive policies whether newly implemented or in place for the entire study period.
There are a number of potential explanations for this unexpected finding. First, policy implementation by AMCs may influence prescribing less than other factors including comparative effectiveness research, regulatory warnings, media attention to fraudulent marketing, patient preferences and characteristics, 32 physician training and prescribing volume, 33 professional guidelines, 34 and FDA advisories. 35 We chose a difference-in-differences analysis approach to try to account for these secular trends.
A second potential explanation is that AAMC recommendations may not be stringent enough to impact physician prescribing behavior. Indeed, stricter policies such as banning all pharmaceutical samples and visits from sales rep-resentatives have been proposed and may have a stronger effect. 36 The billions in pharmaceutical industry promotion and payments that physicians receive from the pharmaceutical industry likely exert substantial influence on prescribing. 37 Industry influence is controversial, however, with some pointing to promotion as necessary for the diffusion of novel and important discoveries 38 and others positing that marketing primarily drives prescribing of more expensive drugs. 39 It remains intuitive that whether marketing practices influence prescribing, policies that restrict marketing may result in a change in physician prescribing patterns, yet COI guidelines lacked measurable goals or expectations for changes in prescribing. Even the strictest institutional policies will not impact physician exposure to marketing within medical journals or at professional conferences, nor would such policies change patient exposure to direct to consumer marketing. 40 Third, the majority of heavily promoted antipsychotics were approved in the 1990s; thus prescribing patterns in this category may have been established before the adoption of COI policies in the late 2000s. To address this issue, we separately examined prescribing of newly introduced and reformulated antipsychotics. Again, we found that exposure to AAMC-compliant policies had little impact on prescribing and all study groups greatly increased their prescribing of new and reformulated antipsychotics over the study period. In fact, physicians in AAMC-compliant centers had slightly larger increases in use of new or reformulated antipsychotics than those in never-compliant centers. We cannot rule out the possibility that some AMCs implemented strict policies in response to rapid adoption of new or reformulated products in their area and that these trends continued even after strict policy adoption. We did find that prescribing of new and reformulated antipsychotics was comparatively higher among nonacademic psychiatrists, which may be due to shifting pharmaceutical marketing strategies, slower uptake of new medications by low-volume prescribers, and community physicians' preference to offer the newest treatments. Community psychiatrists practicing in outpatient settings may also be subject to different formulary restrictions. A fourth potential explanation is that policies may have a greater impact on trainees than on practicing physicians, which is supported by the only 2 prior studies. Trainees may be a focus of marketing as their practices patterns are still forming; however, COI policies generally apply equally to physicians in training and attending physicians and trainee behavior is also likely to be modeled after their instructors. Simultaneous with strict policy implementation, education and awareness of COI issues have increased over time and are now frequently a component of medical education. 26 As both prior studies of trainees compare different generations of trainees, their difference-indifferences analyses adjust for secular trends but not cohort effects. [14] [15] This study has important limitations. First, we measure exposure to policies by affiliation with an AMC; however, we cannot capture the extent to which institutions enforce or educate faculty on new policies nor how application of policies may differ within or across institutions. In fact, 1 survey found minimal change in medical student reporting of exposure to promotion despite strict policies restricting marketing. 13 This study measures exposure to policies aimed at reducing the influence of specific marketing practices; however, we are unable to directly measure physician exposure to marketing. Relatedly, we are unable to assess nonacademic psychiatrists' exposure to COI policies. Furthermore, the Xponent dataset has strengths in broad capture of both volume of prescriptions and individual prescribers; however, it lacks patient-level data on diagnosis or indication for prescription of a medication, and on whether the prescription is new or refilled. As a result we are unable to examine prescribing for on versus off-label uses. Finally, our findings may not be generalizable to other specialties or drug classes. We studied only psychiatrists, and focused solely on prescribing of antipsychotics, one of the most prescribed and most heavily marketed drug classes. Therapeutic options are more numerous and guidelines for selection of therapy less pronounced than in some other major drug classes.
Our study finds minimal impact of policies that restrict marketing practices on prescribing of antipsychotics, one of the most heavily marketed drug classes. These finding suggest that the intended goals and implementation of restrictive COI policies may need to be reassessed and their implementation may need to be revised.
